SWOG clinical trial number
SWOG-9237

Evaluation of Topotecan in Resistant and Relapsing Multiple Myeloma, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Topotecan in Resistant and Relapsing MM
Activated
03/01/1993
Closed
02/15/1995

Research committees

Myeloma

Treatment

Topotecan

Publication Information Expand/Collapse

1998

Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study.

EH Kraut;JJ Crowley;JL Wade;LR Laufman;M Alsina;SA Taylor;SE Salmon Journal of Clinical Oncology 16(2):589-592

1995

Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study.

E Kraut;J Crowley;J Wade;L Laufman;G Weiss;S Taylor;S Salmon Blood 86(10)(Supl.1)(#726):185a

Other Clinical Trials

SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
10%
Open
Phase